润达医疗
(603108)
| 流通市值：106.54亿 | | | 总市值：106.54亿 |
| 流通股本：5.99亿 | | | 总股本：5.99亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,890,332,466.4 | 4,521,325,952.24 | 2,178,109,255.75 | 10,494,418,694.58 |
| 营业收入 | 6,890,332,466.4 | 4,521,325,952.24 | 2,178,109,255.75 | 10,494,418,694.58 |
| 二、营业总成本 | 6,503,471,481.03 | 4,217,930,198.11 | 2,039,063,187.87 | 9,643,284,402.5 |
| 营业成本 | 5,109,831,024.35 | 3,300,781,706.63 | 1,590,530,326.73 | 7,557,066,737.67 |
| 税金及附加 | 31,935,518.56 | 21,974,588.34 | 11,567,573.51 | 38,435,136.14 |
| 销售费用 | 683,916,510.8 | 452,699,584.34 | 212,513,744.51 | 1,036,710,394.62 |
| 管理费用 | 334,074,973.76 | 219,809,346.3 | 108,373,903.18 | 541,262,109.28 |
| 研发费用 | 103,178,932.82 | 65,941,195.98 | 32,638,835.84 | 146,219,073.35 |
| 财务费用 | 240,534,520.74 | 156,723,776.52 | 83,438,804.1 | 323,590,951.44 |
| 其中:利息费用 | 251,275,181.95 | 165,903,732.85 | 84,150,499.8 | 317,922,873.38 |
| 其中:利息收入 | 14,155,668.15 | 8,368,002.05 | 3,634,124.18 | 8,230,961.57 |
| 加:投资收益 | 190,288,942.37 | 68,096,217.37 | 27,477,619.79 | 137,047,924.31 |
| 资产处置收益 | 10,733,572.55 | 7,489,481.88 | 2,354,246.98 | 6,175,447.87 |
| 资产减值损失(新) | -364,520.8 | -188,041 | - | -40,772,298.12 |
| 信用减值损失(新) | -67,614,867.79 | -54,170,900.23 | -25,774,611.78 | -179,855,694.8 |
| 其他收益 | 25,405,307.65 | 15,754,174.09 | 9,052,231.33 | 42,642,910.8 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 545,309,419.35 | 340,376,686.24 | 152,155,554.2 | 816,372,582.14 |
| 加:营业外收入 | 13,207,366.14 | 9,512,258.63 | 7,138,255.31 | 19,059,945.04 |
| 减:营业外支出 | 3,873,400.27 | 1,949,392.99 | 1,448,026.47 | 15,781,235.1 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 554,643,385.22 | 347,939,551.88 | 157,845,783.04 | 819,651,292.08 |
| 减:所得税费用 | 140,979,329.12 | 86,615,817.19 | 38,498,579.21 | 164,541,222.1 |
| 六、净利润 | 413,664,056.1 | 261,323,734.69 | 119,347,203.83 | 655,110,069.98 |
| 持续经营净利润 | 413,664,056.1 | 261,323,734.69 | 119,347,203.83 | 655,110,069.98 |
| 归属于母公司股东的净利润 | 283,453,202.57 | 174,978,854.64 | 81,035,808.45 | 417,746,458.24 |
| 少数股东损益 | 130,210,853.53 | 86,344,880.05 | 38,311,395.38 | 237,363,611.74 |
| (一)基本每股收益 | 0.49 | 0.3 | 0.14 | 0.72 |
| (二)稀释每股收益 | 0.48 | 0.3 | 0.14 | 0.7 |
| 八、其他综合收益 | -2,568,136.66 | -4,098,789.52 | 623,631.58 | 3,090,357.62 |
| 归属于母公司股东的其他综合收益 | -2,273,840.15 | -3,633,804.86 | 546,783.55 | 3,181,474.66 |
| 九、综合收益总额 | 411,095,919.44 | 257,224,945.17 | 119,970,835.41 | 658,200,427.6 |
| 归属于母公司股东的综合收益总额 | 281,179,362.42 | 171,345,049.78 | 81,582,592 | 420,927,932.9 |
| 归属于少数股东的综合收益总额 | 129,916,557.02 | 85,879,895.39 | 38,388,243.41 | 237,272,494.7 |
| 公告日期 | 2023-10-27 | 2023-08-30 | 2023-04-27 | 2023-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |